Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT4 receptor. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma. Indications Montelukast is indicated for the prophylaxis and chronic treatment of asthma in
More
The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use
The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment
More
Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT4 receptor. Cysteinyl leukotrienes and
More
